

James L Gulley

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5539410/james-l-gulley-publications-by-citations.pdf>

Version: 2023-02-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

439
papers

15,396
citations

67
h-index

112
g-index

496
ext. papers

18,164
ext. citations

5.1
avg, IF

6.57
L-index

#	Paper	IF	Citations
439	Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1099-105	2.1	792
438	Androgen deprivation therapy for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 238-44	26.8	696
437	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2117-2124	2.1	417
436	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 51-64	20.9	356
435	Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 3353-62	12.3	322
434	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology, The</i> , 2012 , 13, 501-8	20.9	301
433	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. <i>Cancer Immunology Research</i> , 2015 , 3, 1148-1157	11.9	281
432	Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2532-9	2.1	279
431	Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. <i>Journal of Clinical Oncology</i> , 2005 , 23, 720-31	2.1	254
430	A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 1260-9	12.3	254
429	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 663-74	7.1	252
428	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <i>Lancet Oncology, The</i> , 2017 , 18, 599-610	20.9	220
427	Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. <i>Prostate</i> , 2002 , 53, 109-17	4	192
426	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 1287-1295	12.3	191
425	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology, The</i> , 2017 , 18, 587-598	20.9	200
424	Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. <i>Clinical Cancer Research</i> , 2011 , 17, 907-17	12.3	188
423	Cancer vaccines: moving beyond current paradigms. <i>Clinical Cancer Research</i> , 2007 , 13, 3776-82	12.3	186

4 ²²	Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 3060-9	12.3	179
4 ²¹	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. <i>JAMA Oncology</i> , 2019 , 5, 393-401	12.9	172
4 ²⁰	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1001-11	5.7	159
4 ¹⁹	A phase II clinical trial of sorafenib in androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 209-14	12.3	153
4 ¹⁸	A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. <i>Clinical Cancer Research</i> , 2007 , 13, 958-64	12.3	143
4 ¹⁷	Current Landscape of Immunotherapy in Breast Cancer: A Review. <i>JAMA Oncology</i> , 2019 , 5, 1205-1214	12.9	140
4 ¹⁶	An update on androgen deprivation therapy for prostate cancer. <i>Endocrine-Related Cancer</i> , 2010 , 17, R305-15	5.5	129
4 ¹⁵	Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2070-6	2.1	126
4 ¹⁴	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations 2018 , 6, 141		122
4 ¹³	Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. <i>Clinical Cancer Research</i> , 2008 , 14, 4526-31	12.3	123
4 ¹²	Enhanced functionality of CD4 ⁺ CD25 ^(high) FoxP3 ⁺ regulatory T cells in the peripheral blood of patients with prostate cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 1032-40	12.3	119
4 ¹¹	Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. <i>Cancer Biology and Therapy</i> , 2006 , 5, 22-7	4.4	119
4 ¹⁰	Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2007 , 12, 4957-71	2.7	118
4 ⁰⁹	Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. <i>Oncologist</i> , 2010 , 15, 969-75	5.5	116
4 ⁰⁸	Clinical safety of a viral vector based prostate cancer vaccine strategy. <i>Journal of Urology</i> , 2007 , 178, 1515-20	1.5	109
4 ⁰⁷	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease 2018 , 6, 35		106
4 ⁰⁶	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. <i>Oncolimmunology</i> , 2013 , 2, e27025	6.9	106
4 ⁰⁵	A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. <i>Seminars in Oncology</i> , 2001 , 28, 62-66	5.3	104

404	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.3	103
403	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017 , 23, 6764-6770	12.3	103
402	Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. <i>Cancer Investigation</i> , 2009 , 27, 221-6	2.1	102
401	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2009 , 103, 1636-40	5.4	102
400	Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. <i>Clinical Cancer Research</i> , 2008 , 14, 5284-91	12.3	98
399	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1051-1061	2.1	96
398	Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. <i>Journal of Urology</i> , 2005 , 174, 539-46	1.5	98
397	Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. <i>Clinical Cancer Research</i> , 2011 , 17, 3884-91	12.3	97
396	A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7164-73	12.3	93
395	Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. <i>Cancer Immunology Research</i> , 2014 , 2, 133-41	11.9	92
394	Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. <i>Journal of Urology</i> , 2008 , 179, 2181-5; discussion 2185-6	1.5	91
393	Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. <i>Cancer Research</i> , 2006 , 66, 1844-50	9.6	88
392	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. <i>Cancer Immunology Research</i> , 2015 , 3, 1248-56	11.9	88
391	Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5533-5533	2.1	86
390	A phase II study of perifosine in androgen independent prostate cancer. <i>Cancer Biology and Therapy</i> , 2005 , 4, 1133-7	4.4	88
389	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019 , 25, 6916-6924	12.3	85
388	A retrospective study of the time to clinical endpoints for advanced prostate cancer. <i>BJU International</i> , 2005 , 96, 985-9	5.4	88
387	A novel bifunctional anti-PD-L1/TGF- β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. <i>Oncotmunology</i> , 2017 , 6, e1349589	6.9	87

386	Dual targeting of TGF- β and PD-L1 via a bifunctional anti-PD-L1/TGF- β agent: status of preclinical and clinical advances 2020 , 8,		88
385	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors 2019 , 7, 240		81
384	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. <i>JAMA Oncology</i> , 2019 , 5, 351-357	12.9	81
383	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. <i>Blood</i> , 2012 , 120, 3030-8	2.1	79
382	SUN-739 Next Generation AR Antagonists Increase Systemic Active Glucocorticoid Exposure by Altering Glucocorticoid Metabolism. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.3	78
381	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial 2018 , 6, 111		79
380	Impact of tumour volume on the potential efficacy of therapeutic vaccines. <i>Current Oncology</i> , 2011 , 18, e150-7	2.7	75
379	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , 2016 , 7, 37762-37772	3.2	75
378	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 407-18	7.1	72
377	If we build it they will come: targeting the immune response to breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 37	7.5	73
376	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 225-34	7.1	69
375	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 99-109	12.3	68
374	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5509-5509	2.1	63
373	Clinical evaluation of TRICOM vector therapeutic cancer vaccines. <i>Seminars in Oncology</i> , 2012 , 39, 296-304	3.3	66
372	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , 2018 , 124, 2010-2017	6.3	61
371	Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 886-92	8.6	64
370	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019 , 24, 1259-1269	5.5	64
369	A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. <i>Journal of Urology</i> , 2005 , 173, 1567-71	1.5	64

368	Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. <i>Oncology</i> , 2008 , 22, 1064-70; discussion 1075, 1080-1, 1084	1.2	64
367	A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. <i>Journal of Urology</i> , 2005 , 173, 790-6	1.5	62
366	Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. <i>Clinical Cancer Research</i> , 2002 , 8, 41-53	12.3	60
365	PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 543-54	5.2	59
364	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 1087-95	12.9	57
363	Enhancing efficacy of therapeutic vaccinations by combination with other modalities. <i>Vaccine</i> , 2007 , 25 Suppl 2, B89-96	3.9	59
362	A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. <i>BJU International</i> , 2008 , 102, 617-21	5.4	57
361	A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. <i>Clinical Cancer Research</i> , 2004 , 10, 2139-49	12.3	57
360	The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1175-84	8.6	56
359	Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 365-369	5.4	52
358	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody 2017 , 5, 20		56
357	White paper on microbial anti-cancer therapy and prevention 2018 , 6, 78		56
356	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 150-152	2.3	53
355	Therapeutic cancer vaccines. <i>Advances in Cancer Research</i> , 2014 , 121, 67-124	5.7	48
354	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 197-206	7.1	48
353	Phase I study of oral lenalidomide in patients with refractory metastatic cancer. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 650-60	2.8	44
352	A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015 , 116, 546-55	5.4	46
351	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial 2019 , 7, 12		45

350	Prostate cancer immunotherapy. <i>Clinical Cancer Research</i> , 2011 , 17, 5233-8	12.3	44
349	A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. <i>Clinical Cancer Research</i> , 2010 , 16, 4046-56	12.3	45
348	TRICOM vector based cancer vaccines. <i>Current Pharmaceutical Design</i> , 2006 , 12, 351-61	3.1	46
347	Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells. <i>Journal of Immunology</i> , 2015 , 194, 4215-21	5.2	44
346	Serum antibodies to blood group A predict survival on PROSTVAC-VF. <i>Clinical Cancer Research</i> , 2013 , 19, 1290-9	12.3	43
345	Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. <i>Journal of Immunology</i> , 2013 , 190, 6250-8	5.2	43
344	The use of bisphosphonates in cancer patients. <i>Acta Oncologica</i> , 2007 , 46, 581-91	3.1	41
343	Costimulatory molecules as adjuvants for immunotherapy. <i>Frontiers in Bioscience - Landmark</i> , 2006 , 11, 788-803	2.7	42
342	Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 124-125	2.1	42
341	Therapeutic vaccines: the ultimate personalized therapy?. <i>Human Vaccines and Immunotherapeutics</i> , 2013 , 9, 219-21	4.3	41
340	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1210-1222	2.3	41
339	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , 2007 , 99, 1047-55	5.4	41
338	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma 2019 , 7, 269		41
337	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce 2020 , 8,		41
336	Combining radiation and immunotherapy for synergistic antitumor therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2009 , 11, 37-42		40
335	Paradigm shifts in cancer vaccine therapy. <i>Experimental Biology and Medicine</i> , 2008 , 233, 522-34	3.6	41
334	Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. <i>Critical Reviews in Immunology</i> , 2007 , 27, 451-62	1.7	41
333	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. <i>Clinical Cancer Research</i> , 2017 , 23, 6833-6845	12.3	39

332	Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2013 , 111, 1269-80	5.4	38
331	Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. <i>Clinical Cancer Research</i> , 2005 , 11, 1597-607	12.3	38
330	A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. <i>European Urology</i> , 2015 , 68, 365-71	9.9	38
329	Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer 2018 , 6, 91		37
328	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E1749-58	11.1	36
327	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8503-8503	2.1	39
326	A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). <i>Clinical Breast Cancer</i> , 2006 , 7, 176-9	2.9	35
325	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019 , 16, 745-756	5.3	34
324	A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. <i>Journal of Urology</i> , 2009 , 181, 1104-13; discussion 1113	1.5	35
323	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 2219-31	4.3	32
322	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 77-85	3.2	33
321	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. <i>Journal of Circulating Biomarkers</i> , 2016 , 5, 5	3.3	32
320	Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 109-17	7.1	32
319	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3672-3684 ^{2.1}		32
318	A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 163-163	2.1	31
317	Therapeutic vaccines for prostate cancer. <i>Oncologist</i> , 2006 , 11, 451-62	5.5	33
316	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1521-31	7.1	33
315	Poxviral vectors for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 463-78	5.2	31

314	Analyses of functions of an anti-PD-L1/TGFB2 bispecific fusion protein (M7824). <i>Oncotarget</i> , 2017 , 8, 75217-75231	3.2	31
313	Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. <i>Journal of Urology</i> , 2008 , 180, 1432-7; discussion 1437	1.5	30
312	Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , 2016 , 7, 69014-69023	3.2	30
311	A Prospective Comparison of F-Sodium Fluoride PET/CT and PSMA-Targeted F-DCFBC PET/CT in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1665-1671	8.6	30
310	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial 2019 , 7, 275		29
309	Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. <i>Molecular Imaging</i> , 2019 , 18, 1536012119829986	3.6	29
308	Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. <i>Clinical Lung Cancer</i> , 2010 , 11, 228-37	4.8	28
307	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , 2020 , 25, 290-300	5.5	28
306	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. <i>Onc Immunology</i> , 2016 , 5, e1107698	6.9	27
305	A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. <i>Journal of Urology</i> , 2010 , 183, 2219-26	1.5	27
304	Strategies for improving the management of immune-related adverse events 2020 , 8,		27
303	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2020 , 21, 1099-1109	20.9	28
302	Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. <i>Pharmacotherapy</i> , 2003 , 23, 315-8	5.6	27
301	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2019 , 25, 4933-4944	12.3	25
300	Hepcidin, anaemia, and prostate cancer. <i>BJU International</i> , 2011 , 107, 678-9	5.4	25
299	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 19-28	5.2	26
298	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma 2016 , 4, 92		25
297	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016 , 4, 755-65	11.9	25

296	ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. <i>International Journal of Cancer</i> , 2017 , 141, 583-593	7.3	27
295	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. <i>Oncotarget</i> , 2015 , 6, 31344-59	3.2	24
294	A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. <i>Clinical Prostate Cancer</i> , 2004 , 2, 241-3		24
293	Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. <i>Expert Review of Vaccines</i> , 2018 , 17, 697-705	5	23
292	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019 , 15, 891-908	4.3	22
291	Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2013 , 133, 373-82	7.3	22
290	New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 63-71	7.1	23
289	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , 2020 , 25, 479-e899	5.5	22
288	Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 367-367	2.1	23
287	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 2469-74	4.3	22
286	Promising novel immunotherapies and combinations for prostate cancer. <i>Future Oncology</i> , 2009 , 5, 187- 96 4		22
285	PSA-based vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2006 , 5, 199-209	5	22
284	Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. <i>American Journal of Therapeutics</i> , 2003 , 10, 228-32	0.9	21
283	Pan-Bcl-2 inhibitor, GX15-070 (obatoclox), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. <i>Journal of Immunology</i> , 2014 , 192, 2622-33	5.2	21
282	Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 161-74	7.1	21
281	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort 2020 , 8,		21
280	Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3064-3064	2.1	20
279	Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 229-37	3.2	19

278	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 1409-18	5.2	20
277	Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4501-4501	2.1	21
276	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3044-3044	2.1	19
275	Treatment options for androgen-independent prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2003 , 1, 49-57	0.6	20
274	Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016 , 118, 590-7	5.4	19
273	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolmunology</i> , 2016 , 5, e1197459	6.9	19
272	Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. <i>Expert Review of Vaccines</i> , 2011 , 10, 141-50	5	19
271	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in patients with human papillomavirus-associated malignancies 2020 , 8,		19
270	Vaccines as an Integral Component of Cancer Immunotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2195-2196	26.8	18
269	The role of soluble CD40L in immunosuppression. <i>Oncolmunology</i> , 2013 , 2, e22546	6.9	18
268	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis 2020 , 8,		18
267	Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4). <i>International Journal of Cancer</i> , 2007 , 121, 595-605	7.3	18
266	Chemotherapy for prostate cancer: finally an advance!. <i>American Journal of Therapeutics</i> , 2004 , 11, 288-94.9		18
265	Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report 2018 , 6, 150		17
264	Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. <i>Cancer Journal (Sudbury, Mass)</i> , 2013 , 19, 50-8	2.1	18
263	Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. <i>Oncolmunology</i> , 2012 , 1, 1167-1168	6.9	17
262	Maturation of human dendritic cells with <i>Saccharomyces cerevisiae</i> (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. <i>Vaccine</i> , 2011 , 29, 4992-9	3.9	18
261	Augmented Radiologist Workflow Improves Report Value and Saves Time: A Potential Model for Implementation of Artificial Intelligence. <i>Academic Radiology</i> , 2020 , 27, 96-105	4.2	20

260	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 562-573	9.3	17
259	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer 2020 , 8,		17
258	Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF- β in patients with HPV associated cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3007-3007	2.1	17
257	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. <i>ELife</i> , 2020 , 9,	8.6	17
256	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 694-700	2.7	16
255	Immunotherapy biomarkers 2016: overcoming the barriers 2017 , 5, 29		17
254	Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. <i>Therapeutic Advances in Vaccines</i> , 2014 , 2, 137-48		16
253	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis 2019 , 7, 119		15
252	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2011 , 10, 743-53	5	17
251	Future directions in tumor immunotherapy: CTLA4 blockade. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 136-7		15
250	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 895-901	5.2	14
249	Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3055-3055	2.1	14
248	Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3006-3006	2.1	14
247	Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 403-5	3.2	13
246	Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1106; author reply 1109-12	9.3	13
245	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2014 , 3, 403-5	4.3	13
244	Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. <i>Asian Journal of Andrology</i> , 2014 , 16, 364-71	2.7	14
243	Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research. <i>Cancer</i> , 2016 , 122, 1728-34	6.2	12

242	Exploiting synergy: immune-based combinations in the treatment of prostate cancer. <i>Frontiers in Oncology</i> , 2014 , 4, 351	5.1	13
241	IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 454861		12
240	Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2012 , 15, 289-95	5.9	12
239	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021 , 80, 746-757	9.9	12
238	ABO blood type correlates with survival on prostate cancer vaccine therapy. <i>Oncotarget</i> , 2015 , 6, 32244-56	5.6	12
237	Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 ,	6.8	12
236	A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 102-102	2.1	12
235	Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient. <i>Urology</i> , 2003 , 62 Suppl 1, 147-54	1.5	12
234	Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1505-12	6.4	11
233	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4514-4514	2.1	11
232	Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. <i>Future Oncology</i> , 2005 , 1, 19-22	3.4	11
231	The evolving role of immunotherapy in prostate cancer. <i>Current Opinion in Oncology</i> , 2016 , 28, 232-40	4	10
230	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. <i>OncolImmunology</i> , 2014 , 3, e28611	6.9	11
229	Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. <i>JAMA Network Open</i> , 2020 , 3, e200032	10.1	10
228	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020 , 11, 837	16.9	10
227	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. <i>Oncologist</i> , 2020 , 25, 560-e1006	5.5	10
226	M7824: A promising new strategy to combat cancer immune evasion. <i>Oncoscience</i> , 2018 , 5, 269-270	0.8	10
225	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3055-3055	2.1	9

224	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β in patients with heavily pretreated CRC: Preliminary results from a phase I trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 764-764	2.1	10
223	Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 347-50	3.2	10
222	Novel therapeutic strategies in prostate cancer. <i>Cancer Biology and Therapy</i> , 2004 , 3, 371-6	4.4	10
221	Novel clinical trials in androgen-independent prostate cancer. <i>Clinical Prostate Cancer</i> , 2002 , 1, 51-7		10
220	Perspectives on the clinical development of immunotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , 2018 , 20, 253-259	2.7	10
219	Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. <i>Immunotherapy</i> , 2011 , 3, 27-31	3.6	9
218	The current and emerging role of immunotherapy in prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2010 , 8, 10-6	3.2	9
217	Vaccines as monotherapy and in combination therapy for prostate cancer. <i>Clinical and Translational Science</i> , 2010 , 3, 116-22	4.8	9
216	Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. <i>Annals of Oncology</i> , 2020 , 31, 369-376	2.1	11
215	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC) 2021 , 9,		10
214	A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion. <i>Oncotarget</i> , 2018 , 9, 37676-37688	3.2	9
213	Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF- β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies 2019 ,		5
212	Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. <i>Expert Review of Vaccines</i> , 2003 , 2, 483-93	5	9
211	Resources Required for Semi-Automatic Volumetric Measurements in Metastatic Chordoma: Is Potentially Improved Tumor Burden Assessment Worth the Time Burden?. <i>Journal of Digital Imaging</i> , 2016 , 29, 357-64	5.1	8
210	Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST. <i>BMC Cancer</i> , 2016 , 16, 672	4.6	8
209	Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. <i>Oncologist</i> , 2013 , 18, 821-2	5.5	7
208	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , 2021 , 26, e847-e858	5.5	8
207	Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2526-2526	2.1	7

206	Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 172-172	2.1	8
205	Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9086-9086	2.1	8
204	National Cancer Institute intramural approach to advanced prostate cancer. <i>Clinical Prostate Cancer</i> , 2002 , 1, 153-62		8
203	Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 219-220	9.3	7
202	Developing immunotherapy strategies in the treatment of prostate cancer. <i>Asian Journal of Urology</i> , 2016 , 3, 278-285	2.5	8
201	Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management 2020 , 8,		7
200	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4534-4534	2.1	8
199	Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5026-5026	2.1	7
198	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. <i>BJU International</i> , 2007 , 99, 525-8	5.4	7
197	Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 1010-1014	2.8	6
196	Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report. <i>BMC Cancer</i> , 2019 , 19, 539	4.6	6
195	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. <i>European Urology Focus</i> , 2018 , 4, 636-638	4.9	6
194	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study 2020 , 8,		6
193	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 552-562	8.6	5
192	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1391-1398	12.3	6
191	Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. <i>American Journal of Therapeutics</i> , 2010 , 17, 176-81	0.9	7
190	Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 314-314	2.1	6
189	Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20106-e20106	2.1	6

188	Avelumab (anti-PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9090-9090	2.1	6
187	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.6	5
186	Immunotherapy in genitourinary malignancies. <i>Current Opinion in Urology</i> , 2016 , 26, 501-7	2.7	5
185	Prostate cancer immunotherapy: the path forward. <i>Current Opinion in Supportive and Palliative Care</i> , 2017 , 11, 225-230	2.5	5
184	Ipilimumab in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 303-13	5.2	5
183	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020 , 11, 490	5.5	5
182	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 258-267.e1	3.2	7
181	Avelumab for the treatment of metastatic Merkel cell carcinoma. <i>Drugs of Today</i> , 2017 , 53, 377-383	2.4	5
180	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 207-207 ^{2.1}	2.1	4
179	Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 57-57	2.1	5
178	NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3081-3081	2.1	5
177	A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4590-TPS4590	2.1	5
176	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4516-4516	2.1	5
175	Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3059-3059	2.1	5
174	Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- β and PD-L1.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2566-2566	2.1	5
173	Immunotherapy for biochemically recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 215-215		5
172	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 248-248	2.1	5
171	Immunotherapy for prostate cancer: what's the future?. <i>Hematology/Oncology Clinics of North America</i> , 2006 , 20, 965-83, xi	3	5

170	A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy. <i>Clinical Genitourinary Cancer</i> , 2006 , 5, 89-92	3.2	5
169	A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. <i>Journal of Immunological Methods</i> , 2003 , 279, 183-92	2.4	5
168	Cancer vaccines: current directions and perspectives in prostate cancer. <i>Current Opinion in Molecular Therapeutics</i> , 2009 , 11, 31-6		5
167	Deep Small Bowel Segmentation with Cylindrical Topological Constraints.. <i>Lecture Notes in Computer Science</i> , 2020 , 12264, 207-215	0.8	5
166	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016 2017 , 5, 55		4
165	Prospects for the future of prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2016 , 15, 271-4	5	4
164	(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 347	9.3	4
163	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. <i>International Journal of Cancer</i> , 2014 , 135, 862-70	7.3	4
162	Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer. <i>Cancers</i> , 2012 , 4, 1333-48	6.3	4
161	Progress in prostate cancer imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 938-9	2.7	4
160	Efficacy and immune-related adverse event associations in avelumab-treated patients 2020 , 8,		4
159	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021 , 27, 429-437	12.3	3
158	Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 581801	5.1	4
157	A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 307-307	2.1	4
156	Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy for biochemically recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 214-214	2.1	4
155	A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11527-11527	2.1	4
154	Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9558-9558	2.1	5
153	Clodronate in the prevention and treatment of skeletal metastasis. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 221-30	3.4	4

152	The emerging role of bisphosphonates in prostate cancer. <i>American Journal of Therapeutics</i> , 2004 , 11, 60-73	0.9	4
151	A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e549-e552	3.2	3
150	Moving the goal posts in prostate cancer trials. <i>Lancet Oncology, The</i> , 2015 , 16, 247-9	20.9	3
149	MP15-10 IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL. <i>Journal of Urology</i> , 2017 , 197,	1.5	3
148	Dramatic and prolonged PSA response after retreatment with a PSA vaccine. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 362-4	3.2	3
147	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1769-81	5.2	3
146	Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 43-6	3.2	3
145	Adding fuel to the fire: immunogenic intensification. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 3306-12	4.3	3
144	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021 , 127, 435-444	5.4	3
143	A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS192-TPS192 ³	2.1	3
142	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin@ lymphoma 2021 , 9,		3
141	Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivolpi) for metastatic genitourinary tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3-3	2.1	3
140	Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2501-2501	2.1	3
139	Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4569-4569	2.1	3
138	Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS5081-TPS5081	2.1	3
137	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 166-166	2.1	3
136	PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 105-105	2.1	3
135	Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature. <i>American Journal of Therapeutics</i> , 2007 , 14, 310-3	0.9	3

134	A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 72-5 ^{3.7}	3
133	Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy. <i>American Journal of Therapeutics</i> , 2005 , 12, 172-4	0.9 3
132	Therapeutic prostate cancer vaccines: a review of the latest developments. <i>Current Opinion in Investigational Drugs</i> , 2008 , 9, 1296-301	3
131	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 1429-35	7.1 2
130	Toward an off-the-shelf vaccine for B-cell malignancies. <i>Blood</i> , 2012 , 120, 1539-40	2.1 2
129	Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma. <i>Cancer Gene Therapy</i> , 2020 , 27, 438-447 ^{5.2}	2
128	Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report. <i>Frontiers in Oncology</i> , 2020 , 10, 603248	5.1 2
127	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. <i>IEEE Access</i> , 2021 , 9, 87531-87542	3.2 2
126	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS6092-TPS6092	2.1 1
125	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy 2021 , 9,	2
124	Dual PD-L1 and TGF- β blockade in patients with recurrent respiratory papillomatosis 2021 , 9,	2
123	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer 2021 , 9,	2
122	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer 2021 , 9,	2
121	Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5509-5509	2.1 2
120	Infusion-related reactions with administration of avelumab: mild and manageable side effects. <i>Translational Cancer Research</i> , 2017 , 6, S1296-S1298	0.3 2
119	Current perspectives in prostate cancer vaccines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009 , 9, 1052-7	2
118	A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14026-e14026	2.1 2
117	Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3038-3038	2.1 2

116	Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 191-191	2.1	2
115	Vaccine therapy for a patient with androgen-insensitive prostate cancer without evidence of measurable disease on scans. <i>American Journal of Therapeutics</i> , 2004 , 11, 238-41	0.9	2
114	Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100049	1.2	2
113	A comparison of F-DCFPyL, F-NaF and F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.6	2
112	Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial). <i>Human Pathology</i> , 2018 , 78, 72-78	3.6	1
111	mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 352.e25-352.e30	2.7	1
110	Radium-223 in prostate cancer: emitting the right signals. <i>Lancet Oncology, The</i> , 2016 , 17, 1186-7	20.9	1
109	Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned 2013 , 309-331		1
108	970 PROSPECT: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 EFFICACY TRIAL OF PROSTVAC-VF IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2013 , 189,	1.5	1
107	Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells 2013 , 1,		1
106	Prostate cancer: Intermediate efficacy end points to assess modern therapies. <i>Nature Reviews Urology</i> , 2013 , 10, 686-7	5.3	1
105	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020 , 47, 457-467	2.8	1
104	643P Evaluating biomarkers in metastatic castration resistant prostate cancer (mCRPC) patients (Pts) treated with enzalutamide (Enza): PSA, circulating tumor cell (CTC) counts, AR-V7 status, PET imaging vs. CT & Tc99 scans. <i>Annals of Oncology</i> , 2020 , 31, S527-S528	2.1	1
103	681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc). <i>Annals of Oncology</i> , 2020 , 31, S542	2.1	1
102	957O Long-term follow-up of patients (pts) with human papillomavirus (HPV) associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1. <i>Annals of Oncology</i> , 2021 , 32, S829	2.1	1
101	MP16-14 CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE II STUDY TO DETERMINE THE EFFICACY OF BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG GIVEN ALONE IN ADULTS WITH HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2021 , 206,	1.5	1
100	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 601452	5.1	1
99	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic 2021 , 9,		1

98	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6020-6020	2.1	1
97	Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e17044-e17044	2.1	1
96	A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4599-TPS4599	2.1	1
95	A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5096-TPS5096	2.1	1
94	Therapeutic vaccines for prostate cancer: what have we learned?. <i>Therapy: Open Access in Clinical Medicine</i> , 2008 , 5, 3-5		1
93	Analysis of PSA-Specific T-Cell Responses of Prostate Cancer Patients Given a PSA-Based Vaccine on a Clinical Trial 2003 ,		1
92	456 Impact of angiotensin II pathway inhibition on tumor response to anti PD(L)1 based therapy 2020 , 8, A483-A483		1
91	Abstract 5520: Therapeutic vaccination with epitope-enhanced and wild-type TARP peptides in stage D0 prostate cancer 2011 ,		1
90	Abstract 1586: Recovery and characterization of circulating tumor cells (CTCs) in cryopreserved metastatic castrate-resistant prostate cancer (mCRPC) patient samples 2015 ,		1
89	Abstract 4901: Short-course enzalutamide reveals immune activating properties in patients with biochemically recurrent prostate cancer 2016 ,		1
88	Prospect: A randomized, double-blind, phase III efficacy trial of PROSTVAC.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4699-TPS4699	2.1	1
87	Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4701-TPS4701	2.1	1
86	A phase I trial of a recombinant CEA yeast-based vaccine targeting CEA-expressing cancers.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 458-458	2.1	1
85	A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 117-117	2.1	1
84	Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination with vaccine.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 31-31	2.1	1
83	A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 108-108 ^{2.1}	2.1	1
82	Impact of standard chemotherapy on peripheral blood immune cell subsets in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 597-597	2.1	1
81	Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 235-235	2.1	1

80	Short course enzalutamide monotherapy in biochemically recurrent prostate cancer: Clinical and immunologic impact.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16619-e16619	2.1	1
79	Avelumab in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5037-5037	2.1	1
78	Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3057-3057	2.1	1
77	Effect of rilimogene galvacirepvec/rilimogene glafoivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5083-5083	2.1	1
76	A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS3130-TPS3130	2.1	1
75	Early treatment gets the benefit. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5172-3; author reply 5173	2.1	1
74	Treating systemic prostate cancer: emerging drug targets and therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2000 , 4, 751-763		1
73	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity.. <i>JCI Insight</i> , 2022 , 7,	9.6	1
72	Dual inhibition of TGF- β and PD-L1: a novel approach to cancer treatment. <i>Molecular Oncology</i> , 2021 ,	7.7	1
71	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).. <i>Prostate Cancer and Prostatic Diseases</i> , 2022 ,	5.9	1
70	Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors.. <i>Oncologist</i> , 2022 , 27, e353-e356	5.5	1
69	TRICOM Poxviral-Based Vaccines for the Treatment of Cancer 2014 , 291-327		1
68	Artificial intelligence assisted bone lesion detection and classification in computed tomography scans of prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17567-e17567	2.1	1
67	Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14008-e14008	2.1	
66	Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 128-128	2.1	1
65	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e166-e170	6.8	
64	Vaccines and Immunostimulants 2017 , 1-22		
63	Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 799-800	9.3	1

62	Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 92-92	2.1	1
61	Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 93-93	2.1	0
60	Tumor in the Crossfire: Inhibiting TGF- β to Enhance Cancer Immunotherapy.. <i>BioDrugs</i> , 2022 , 36, 153	7.7	0
59	A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.. <i>Oncologist</i> , 2022 , 27, 198-209	5.5	0
58	MPA software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.. <i>Cell Reports Methods</i> , 2022 , 2, 100136		0
57	Ferumoxytol enhanced MRI for lymph node staging in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 208-208	2.1	
56	A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10589-10589	2.1	
55	Preliminary results of a prospective study of 18F-NAF PET/CT in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 103-103	2.1	
54	Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFBII agent: Current status.. <i>Experimental Biology and Medicine</i> , 2022 , 15353702221089910	3.6	0
53	Pembrolizumab: patient selection or immune intensification?. <i>Nature Reviews Urology</i> , 2018 , 15, 593-594	5.3	
52	The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors 2014 , 315-334		
51	Nuts and Bolts of Cancer Immunotherapy 2014 , 826-830		
50	Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment. <i>Cancer Drug Discovery and Development</i> , 2014 , 553-568	0.3	
49	Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing 2013 , 621-642		
48	Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. <i>Clinical Investigation</i> , 2013 , 3, 651-663		
47	Combining radiation and therapeutic cancer vaccines: a synergistic approach. <i>Breast Cancer Management</i> , 2012 , 1, 325-335	0.7	
46	Reply to L. LeBlanc et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e417-e417	2.1	
45	14937 Keratoacanthomas associated with anti-TGF- β immunotherapy. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, AB24	3.4	

44 PSA **2017**, 451-45843 In Reply. *Oncologist*, **2021**, 26, e192-e193 5.542 CD4+ T-cell count eligibility by HIV status among participants receiving immunotherapy for cancer diagnoses.. *Journal of Clinical Oncology*, **2021**, 39, 12104-12104 2.141 605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide. *Annals of Oncology*, **2021**, 32, S647 2.140 A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.. *Journal of Clinical Oncology*, **2021**, 39, 2617-2617 2.139 Even more cost savings?. *Journal of Oncology Practice*, **2006**, 2, 202 338 therapeutic vaccines for colorectal cancer. *American Journal of Cancer*, **2004**, 3, 299-31637 A rare insight into the immunosuppressive landscape of prostate cancer bone metastases. *Cancer Cell*, **2021**, 39, 1450-1452 23.136 Resistance to Immunotherapy: Mechanisms and Means for Overcoming.. *Advances in Experimental Medicine and Biology*, **2021**, 1342, 45-80 3.435 A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures.. *Journal of Clinical Oncology*, **2020**, 38, 368-368 2.134 Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.. *Journal of Clinical Oncology*, **2020**, 38, e17569-e17569 2.133 Spatial analysis of tumor immune microenvironment (TIME) in patients treated with Bintrafusp alfa.. *Journal of Clinical Oncology*, **2020**, 38, 3070-3070 2.132 Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).. *Journal of Clinical Oncology*, **2020**, 38, 85-85 2.131 The effect of deep AR suppression with enzalutamide or apalutamide on endogenous glucocorticoids: Implications for adverse effects and development of combination therapies.. *Journal of Clinical Oncology*, **2020**, 38, 17-17 2.130 Validation of a software-based clinical trial matching platform for oncology using comprehensive clinical information.. *Journal of Clinical Oncology*, **2018**, 36, e18589-e18589 2.129 Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.. *Journal of Clinical Oncology*, **2018**, 36, e21531-e21531 2.128 Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis.. *Journal of Clinical Oncology*, **2019**, 37, e16536-e16536 2.127 Phase I trial of a modified vaccinia ankara (MVA) priming vaccine followed by a fowlpox virus (FPV) boosting vaccine modified to express brachyury and costimulatory molecules in advanced solid tumors.. *Journal of Clinical Oncology*, **2019**, 37, 2640-2640 2.1

26	A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5074-5074	2.1
25	A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15527-e15527	2.1
24	A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5072-5072	2.1
23	Association of NaF PET/CT findings with PSA and alkaline phosphatase in untreated castration-sensitive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 122-122	2.1
22	Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3101-TPS3101	2.1
21	Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15501-e15501	2.1
20	The impact of age on sipuleucel-T-induced immune responses.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16009-e16009	2.1
19	Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16032-e16032	2.1
18	Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 272-272	2.1
17	An analysis of sodium 18f-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 203-203 ^{2.1}	2.1
16	An analysis of sodium 18F-fluoride PET/CT and prostate specific antigen (PSA) changes in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23149-e23149 ^{2.1}	2.1
15	Personalized peptide vaccine in prostate cancer: capitalizing on existing immunity. <i>Translational Cancer Research</i> , 2016 , 5, S1333-S1335	0.3
14	Cancer Immunology, Immunotherapeutics, and Vaccine Approaches 2010 , 305-319	
13	Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer. <i>Asian Journal of Andrology</i> , 2011 , 13, 657-8	2.7
12	Immunotherapy for prostate cancer 2011 , 54-65	
11	A phase I study of TRC105 (Anti-CD105 [endoglin] antibody) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3043-3043	2.1
10	A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS3638-TPS3638	2.1
9	Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies 2013 , 455-474	

8 PSA **2013**, 1-87 Safety profile of poxviral vaccines: NCI experience.. *Journal of Clinical Oncology*, **2013**, 31, 85-85 2.16 Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR).. *Journal of Clinical Oncology*, **2013**, 31, 132-132 2.15 Safety profile of recombinant poxviral TRICOM vaccines.. *Journal of Clinical Oncology*, **2013**, 31, e16036-e160364 Celebrating a decade of the Journal for ImmunoTherapy of Cancer **2022**, 10, e0052073 Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.. *Journal of Clinical Oncology*, **2014**, 32, 245-245 2.12 A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2014**, 32, 218-218 2.11 ARv567es as detected in circulating tumor cells: An innovative methodology for the detection of a prognostic and therapeutic biomarker.. *Journal of Clinical Oncology*, **2014**, 32, 112-112 2.1